Serotonin warning for users of SSRIs

Share this article:
The FDA says development of a potentially life-threatening serotonin syndrome may occur in treatment with four selective serotonin reuptake inhibitors: Lilly's Cymbalta (duloxetine HCl) delayed release capsules, Wyeth's Effexor (venlafaxine HCL) tablets and Effexor extended release capsules, Lilly's Prozac (fluoxetine capsules and oral solution) and Lilly's Symbyax (olanzapine and fluoxetine HCL capsules).

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.